French collaboration to develop Oncology-targeted Therapy

10/06/2015 - 2 minutes

PEP-Therapy and CleveXel Pharma will co-develop targeted therapy in oncology. The product is based on an innovative technology involving bi-functional peptides that penetrate cells, and specifically block pathological mechanisms without affecting physiological mechanisms.

The drug candidate is a cell-penetrating peptide that targets an interaction between two intracellular proteins, Caspase-9 and PP2A. It has been validated on highly-representative preclinical models for human tumors, such as patient-derived xenograft or PDX models. The approach showed targeted efficacy on cancer cells and an absence of toxicity, especially in triple-negative breast cancer and ovarian cancer.

The partners’ mutual goal is to take the product through to its clinical proof of concept with both costs and benefits being shared.  PEP-Therapy intends to benefit from CleveXel’s acceleration programm. This development system already contains two other oncology candidates that are currently profiting from CleveXel’s expertise.

PEP-Therapy, thanks to this partnership, will accelerate the development of its first product towards its clinical trial phase, which is expected to start at the end of 2016. 

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member